News
News
Dr. Lun Kelvin Tsou receiving the 14th Tien Te Lee Biomedical Young Scientists Award
Dr. Lun Kelvin Tsou, associate Investigator of IBPR. Dr, Tsou with his team members had development a noval small molecule drug conjugate, DBPR115, that could target a biomarker phosphatidylserine and the deliver the anti-tumor agent to the tumor sites. By increasing the concentration of drug around the tumor, to decrease the side effects. Dr. Tsou was awarded the 14th Tien …
A major milestone for cancer drug development in Taivex! T-1101 OPC initiates Phase I clinical study
T-1101 is a First-in-Class Hec1/Nek2 inhibitor that disrupts cancer cell cycle division thereby inhibits tumor growth in the body and receives TFDA approval to initiate Phase I clinical study in Taiwan. Patients with advanced tumors have been enrolled into an ongoing open-label, Phase I dose escalation study in Taiwan. Enrollment for this study in Taiwan started in July 2017. T-1101 …
T-1201 get 2017 Taipei Biotech Award_ Technology Transfer Gold Medal Award
Taivex corporate with Institute of Biotechnology and Pharmaceutical Research (IBPR) at National Health Research Institute, developing a first-in-class small molecule drug, T-1201. This drug had received 2016 Technology Achievement Award (Ministry of Economic Affairs), now get 2017 Taipei Biotech Award_ Technology Transfer Gold Medal Award (Taipei City Government). T-1201 is a noval anti-tumor drug deliver system, that with intellectual property …
T-1101 OPC approved by the TFDA to start Phase I clinical study
Taivex Therapeutics Corp. has identified a novel targeting small molecule anti-cancer drug, T-1101, which is oral powder for constitution (OPC). T-1101 IND application has been approved by FDA in Sept, 2016 and further by TFDA in Jan, 2017. T-1101 acts through disrupting the interaction between Hec1 and Nek2, these proteins involved in mitotic regulation that are highly expressed in cancer cells. …
